Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona diagnoza włóknienia szpiku kostnego
- •Wcześniejsze leczenie włóknienia szpiku lub niewystarczająca odpowiedź na leczenie
- •Diagnoza białaczki monocytowej nieodpowiadającej na standardowe leczenie
- •Prawidłowa funkcja wątroby i nerek
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Podpisana zgoda pacjenta lub jego opiekuna
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The University of Texas M. D. Anderson Cancer Center
Houston, United States
Trial contact
Naveen Pemmaraju, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.